Back to top
more

Sangamo Therapeutics (SGMO)

(Delayed Data from NSDQ)

$0.46 USD

0.46
8,381,653

-0.03 (-5.33%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $0.45 -0.01 (-1.51%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of -14.29% and -9.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Vanda (VNDA) delivered earnings and revenue surprises of -35.29% and -4.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of -27.27% and 29.77%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of 312.68% and 215.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of -22.22% and 52.51%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of 4.71% and 5.36%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 18.18% and 215.37%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of -11.36% and 39.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of 66.67% and 23.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Biogen (BIIB) delivered earnings and revenue surprises of 0.58% and 1.59%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More

by Kinjel Shah

PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.

Zacks Equity Research

Company News for Jan 2, 2025

by Zacks Equity Research

Companies In The News Are: X, BHVN, SGMO, PFE, BLDR.

Zacks Equity Research

SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate

by Zacks Equity Research

Sangamo stock crashes 60.4% as partner Pfizer decides to end collaboration for hemophilia A candidate, giroctocogene fitelparvovec.

Zacks Equity Research

Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of 233.33% and 86.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Beyond Air, Inc. (XAIR) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Beyond Air (XAIR) delivered earnings and revenue surprises of 6.67% and 32.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

ANI (ANIP) delivered earnings and revenue surprises of 22.94% and 3.03%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of 200% and 1.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Cytek Biosciences (CTKB) delivered earnings and revenue surprises of 150% and 1.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of -6.25% and 96.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 18.75% and 12.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of -22.73% and 94.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 12% and 86.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?